Please assess the completion status of the following clinical trial:

Trial Title: PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed metastatic gastric or esophagogastric junction (type I,II,III Siewert) adenocarcinoma~2. Newly-diagnosed chemo-naïve or recurrent after curative-intent surgery~   * \>6 months after completion of adjuvant therapy (including chemotherapy and/or radiotherapy)~  * No prior treatment with any targeted agent~  * Patients who have started first line mFOLFOX6 therapy (+/-trastuzumab for HER2 amplified tumors) may be considered for trial participation if they have received no more than 4 doses of therapy at the time of consent and screening.~3. Measurable metastatic disease by RECIST criteria,~   * Must be amenable to ultrasound or CT-guided biopsy of one metastatic lesion~  * Peritoneal disease as the sole site of occult metastasis or presenting as malignant ascites is acceptable if a cell block of tumor cells can be obtained showing \>20% viable tumor cells.~4. ECOG PS 0,1~5. Age \> 18 years~6. Patients must have normal organ and marrow function as defined below:~   * granulocytes \>1,2500/mcL~  * platelets \>100,000/mcL~  * total bilirubin \< 1.5 x ULN, \<1.8 x ULN with liver metastases~  * AST(SGOT)/ALT(SGPT) \<2.5 X ULN without liver metastases; \<5 X ULN with liver metastases~  * creatinine within normal institutional limits (\<1.5) OR~  * creatinine clearance \>50 mL/min/1.73m2, (for creatinine level above normal)~  * INR: \< 1.5 (patients on warfarin need to be converted to LMWH during study participation to be eligible)~7. Consent to baseline metastatic and progressive disease biopsy (of metastatic/progressing lesion) for enabling biomarker assessment and treatment assignment (at each time point - baseline, PD1, PD2, PD3) as well as for correlative studies.~   • Consent to baseline and serial blood draws for plasma/serum/whole blood banking for correlative studies~8. Ability to understand and the willingness to sign a written informed consent document and consent to the serial nature of the proposed PANGEA treatment with first, second and third line therapy as tolerated.~9. Ability to comply with requirements of the protocol, as assessed by the investigator by the patient signing the consent form.~10. If history of exposure to anthracyclines during perioperative treatment, the following cumulative doses of anthracyclines must be less than:~    Epirubicin \< 720 mg/m2 Doxorubicin or liposomal doxorubicin \< 360 mg/m2 Mitoxantrone \> 120 mg/m2 and idarubicin \> 90 mg/m2 If more than one anthracycline has been used, then the cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.~11. Cardiac Ejection Fraction \>50% (for HER2+ patients) as assessed by echocardiogram, MUGA scan, or cardiac MRI~12. Willingness to use effective and reliable methods of contraception (For appropriate methods of contraception considered acceptable see Appendix B).~Both men and women and members of all races and ethnic groups are eligible for this trial.~Exclusion Criteria:~1. No CVA within 6 months, no recent MI within 6 months~2. No currently active second malignancy~3. No uncontrolled intercurrent illness or infection~4. No peripheral edema \> grade 2 at baseline.~5. No peripheral neuropathy \> grade 2 at baseline.~6. No diarrhea \> grade 2 at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ITT-PTS: Personalized Treatment Strategy (Immuno-oncology) (Type: EXPERIMENTAL): For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:~Immuno-oncology included PD-L1 IHC combined positivity score \>10, high microsatellite instability, tumor mutation burden \>15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab.
- ITT-PTS: Personalized Treatment Strategy (HER2 amplified) (Type: EXPERIMENTAL): HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.
- ITT-PTS: Personalized Treatment Strategy (EFGR amplified) (Type: EXPERIMENTAL): EGFR amplified. These patients received ABT-806.
- ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified) (Type: EXPERIMENTAL): FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.
- ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant) (Type: EXPERIMENTAL): MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.
- ITT-PTS: Personalized Treatment Strategy (EGFR expressing) (Type: EXPERIMENTAL): EGFR expressing. These patients received standard cytotherapy plus ABT 806.
- ITT-PTS: Personalized Treatment Strategy (All negative) (Type: EXPERIMENTAL): All negative. These patients received standard cytotherapy plus Ramucirumab.
- Non-ITT: Standard Therapy (Type: OTHER): Patients without monoclonal antibodies available received standard cytotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete